Our Science

Non-alcoholic steatohepatitis (NASH) is a type of NAFLD (nonalcoholic fatty liver disease), which is the condition with stored excess of fat in liver. NAFLD is characterized by steatosis of the liver, and NASH is a necro-inflammatory process whereby the liver cells become injured  under steatosis.


Prevalence rate of NAFLD in China is estimated at 15.0%, or 208.5 million NAFLD patients, in 2017, and is expected to increase as less exercise and other lifestyle changes in the PRC population increase the risk of obesity.


Although there is a huge patient pool and unmet medical needs, currently there are no approved NASH drugs in the world. We are develop in-house breakthrough therapies for NASH focusing on novel targets.

nba比分 日本棒球比分规则 亿客隆彩票首页 重庆百变王牌 陕西快乐十分 雪缘园nba比分 河北20选5 足球指数北京 足球指数s2 pc蛋蛋 spbo即时比分 江苏十一选五 重庆时时彩 北单比分3串1过滤模式 五体球是什么 体球吧 浙江20选5